206 related articles for article (PubMed ID: 23348804)
21. Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
Arndt S; Veelken H; Schmitt-Gräff A; Aschendorff A; Maier W; Richter B
Ann Otol Rhinol Laryngol; 2007 Apr; 116(4):257-61. PubMed ID: 17491523
[TBL] [Abstract][Full Text] [Related]
22. Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.
Paik JS; Cho WK; Lee SE; Choi BO; Jung SE; Park GS; Kim SH; Yang SW; Cho SG
Ann Hematol; 2012 Sep; 91(9):1393-401. PubMed ID: 22543827
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
24. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
27. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
28. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
29. Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma.
Kahara T; Iwaki N; Kaya H; Kurokawa T; Yoshida T; Ishikura K; Usuda R
Endocr J; 2011; 58(1):7-12. PubMed ID: 21068513
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.
Hashimoto N; Sasaki R; Nishimura H; Yoshida K; Miyawaki D; Nakayama M; Uehara K; Okamoto Y; Ejima Y; Azumi A; Matsui T; Sugimura K
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1509-14. PubMed ID: 21664061
[TBL] [Abstract][Full Text] [Related]
32. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
[TBL] [Abstract][Full Text] [Related]
33. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Zinzani PL; Stefoni V; Musuraca G; Tani M; Alinari L; Gabriele A; Marchi E; Pileri S; Baccarani M
Cancer; 2004 May; 100(10):2190-4. PubMed ID: 15139063
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
[No Abstract] [Full Text] [Related]
36. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Satram-Hoang S; Reyes C; Hoang KQ; Momin F; Skettino S
Ann Hematol; 2014 Aug; 93(8):1335-44. PubMed ID: 24638841
[TBL] [Abstract][Full Text] [Related]
37. Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Olszewski AJ; Desai A
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):642-9. PubMed ID: 24411627
[TBL] [Abstract][Full Text] [Related]
38. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
Tsang RW; Gospodarowicz MK; Pintilie M; Wells W; Hodgson DC; Sun A; Crump M; Patterson BJ
J Clin Oncol; 2003 Nov; 21(22):4157-64. PubMed ID: 14615444
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Mar; 117(11):3016-24. PubMed ID: 21245487
[TBL] [Abstract][Full Text] [Related]
40. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
Conconi A; Martinelli G; Thiéblemont C; Ferreri AJ; Devizzi L; Peccatori F; Ponzoni M; Pedrinis E; Dell'Oro S; Pruneri G; Filipazzi V; Dietrich PY; Gianni AM; Coiffier B; Cavalli F; Zucca E
Blood; 2003 Oct; 102(8):2741-5. PubMed ID: 12842999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
